How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/sepsis-due-to-staphylococcus-aureus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sepsis due to Staphylococcus aureus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sepsis due to Staphylococcus aureus (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sepsis due to Staphylococcus aureus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cubicin	Daptomycin	Baxter	lipopeptide antibacterial		2003-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Bactocill In Plastic Container	OXACILLIN	Apothecon		Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1971-01-01
Nallpen In Plastic Container	NAFCILLIN SODIUM	Pfizer	Penicillin-class Antibacterial		1965-01-01
Nallpen In Plastic Container	NAFCILLIN	Pfizer	Penicillin-class Antibacterial		1965-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Cubicin	Cubicin	Clinical Alliance for Research & Education - Infectious Diseases, LLC.		Outer membrane porin protein OmpD
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Sepsis due to Staphylococcus aureus
Pfizer · 2 drugs in Sepsis due to Staphylococcus aureus
Pai Holdings Pharm · 2 drugs in Sepsis due to Staphylococcus aureus
Baxter Hlthcare Corp · 1 drug in Sepsis due to Staphylococcus aureus
Bristol-Myers Squibb · 1 drug in Sepsis due to Staphylococcus aureus
Clinical Alliance for Research & Education - Infectious Diseases, LLC. · 1 drug in Sepsis due to Staphylococcus aureus
Dr Reddys Labs Inc · 1 drug in Sepsis due to Staphylococcus aureus
Sterimax · 1 drug in Sepsis due to Staphylococcus aureus
Tel-Aviv Sourasky Medical Center · 1 drug in Sepsis due to Staphylococcus aureus
Apothecon · 1 drug in Sepsis due to Staphylococcus aureus
Baxter · 1 drug in Sepsis due to Staphylococcus aureus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sepsis due to Staphylococcus aureus:

Cite this brief

Drug Landscape (2026). Sepsis due to Staphylococcus aureus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sepsis-due-to-staphylococcus-aureus. Accessed 2026-06-10.

Sepsis due to Staphylococcus aureus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing